Oğuz Galip Yildiz

Oğuz Galip Yildiz

Auto-generated profile, based on publicly available information

Oğuz Galip Yildiz

Department of Radiation Oncology, Erciyes University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2022 in International Journal of Radiation Biology
Verified
Journal Article
Closed access
MBMunevver Baran
Munevver Baran
AYArzu Yay
Arzu Yay
GÖGözde Özge Özge Önder
Gözde Özge Özge Önder
FTFazile Canturk Tan
Fazile Canturk Tan
BYBetul Yalcin
Betul Yalcin
OYOguz Galip Yıldız
Oguz Galip Yıldız
Although radiation is one of the basic methods commonly used in cancer treatment, it inevitably enters the field of treatment in healthy tissues and is adversely affected by the acute and chronic s...

28 June 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
NHNazlı Helvacı-Kurt
Nazlı Helvacı-Kurt
HSHatice Saracoglu
Hatice Saracoglu
OYOğuz Galip Yildiz
Oğuz Galip Yildiz
EKEser Kiliç
Eser Kiliç
Targeting the new and unique proteins is an important medical strategy for treating breast cancer. It is quite important to find out proteins that have a role in the development of cancer. Sirtuins (SIRT) are well related in different physiological activities and connected with cancer. We aimed to determine the effect of radiotherapy on SIRT1 and SIRT2, which have not been yet clarified as a tumor suppressor or promoter. 22 women with non-metastatic breast cancer enrolled in the study. Blood samples were taken before and after radiotherapy, soluble SIRT1 and SIRT2 levels were determined with ELISA kits. There was no difference in SIRT1 levels before and after radiotherapy (p=0.548). SIRT2 levels were significantly found to be decreased after radiotherapy (p=0.042). There was a strong and positive correlation before radiotherapy (p<0.001), and a moderate and positive correlation after radiotherapy (p=0.007) between SIRT1 and SIRT2. These results suggest that SIRT2 may provide a new strategy for follow-up of breast cancer treatment. Additionally, by emphasizing the importance of SIRT2 in breast cancer, it opens ways to provide grounds for the development of the next generation of SIRT2-specific radiotracers. Finally, the most important thing in fact, the positive correlation between SIRT1 and SIRT2 both before and after radiotherapy, appears to be clear evidence suggesting more oncogenic roles of sirtuins.

29 July 2025 in Scientific Reports
Verified
Journal Article
Open access
HGHatice Basaran Goksen
Hatice Basaran Goksen
OYOguz Galip Yildiz
Oguz Galip Yildiz
OCOzlem Canoz
Ozlem Canoz
MGMete Gundog
Mete Gundog
CECelalettin Eroglu
Celalettin Eroglu
NTNahit Topaloglu
Nahit Topaloglu
To search the prognostic significance of the neuronatin (NNAT) protein diagnosed with lung adenocarcinoma in the occurence of brain metastasis. Sixty-six of 200 patients diagnosed with lung adenocarcinoma who received radiotherapy (RT) between 2014 and 2017 were included in the study. A total of 66 patients, 33 (50%) with brain pathology and 33 (50%) with lung pathology, were analyzed retrospectively. Furthermore NNAT-immune-reactivity score (IRS) and nuclear positivity were analyzed in terms of pathological factors. In 33 cases where primary tumor pathology was studied, a statistically borderline significant effect was found for the N stage and a statistically significant effect on overall survival (OS) for nuclear positivity. While OS was 7.6 months in nucleus positively stained (PNS) cases, it was 24.4 months in negatively stained (NNS) cases. While the survival of NNAT-IRS positive cases without cranial metastasis was 20.7 months, the survival of the negative group without cranial metastasis was 61.2 months. The survival of cases with PNS without cranial metastasis was 7.1 months, while the survival of cases with NNS results without cranial metastasis was 52.1 months. In cases where intracranial pathologies, the number of intracranial metastases and the presence of extracranial metastases were found to be statistically significant independent factors (p < 0.001, p < 0.001). With NNAT study in initial pathological tissues of patients diagnosed with lung adenocarcinoma, especially nuclear positivity and NNAT-IRS positivity, a strong prediction can be made about the occurrence of brain metastasis.

31 January 2024 in Medical Records
Verified
Journal Article
Open access
PDF file
GÖGözde Özge Özge Önder
Gözde Özge Özge Önder
ABAdnan Bayram
Adnan Bayram
OYOğuz Galip Yildiz
Oğuz Galip Yildiz
AYArzu Yay
Arzu Yay
Aim: We looked at the connection between autophagy and apoptosis after our prior research indicated that melatonin could cause MCF-7 and MDA-MB-231 cells in the present study. Material and Method: In order to investigate the autophagy inhibition’s effect on the melatonin-induced BC cells’ apoptosis, melatonin and/or 3-methyladenine (3-MA, autophagy inhibitor) have been utilized. Melatonin was applied to the cells following a 5-mM 3-MA pre-cultivation. Then, apoptosis was detected by the TUNEL method. The technique for double immunofluorescence labeling was used to identify the molecular alterations in Bax/Bcl-2 expression. To evaluate the cell viability, the MTT test was used. Results: When an autophagy inhibitor, 3-MA, and melatonin treatment were co-administered in MCF-7 cells, apoptosis was decreased, compared to melatonin treatment alone, but it was not significant. In addition, 3-MA application downregulated Bax expression compared with melatonin alone treatment. Combined therapy markedly elevated apoptosis and significantly up-regulated Bax protein in MDA-MB-231 cells. Conclusion: Taken together, in MCF-7 cells, autophagy’s inhibition contributes to the downregulation of apoptosis, whereas increased apoptosis is seen in MDA-MB-231 cells. Inhibiting autophagy in these cells treated with melatonin could serve as a self-defense mechanism, and This might be a good strategy for breast cancer adjuvant treatment.

14 January 2026 in International Journal of Radiation Biology
Verified
Journal Article
Closed access
KBKudret Ensarioğlu Baktır
Kudret Ensarioğlu Baktır
OYOguz Galip Yıldız
Oguz Galip Yıldız
NBNuman Baydilli
Numan Baydilli
EKEda Köseoğlu
Eda Köseoğlu
KYKadir Yaray
Kadir Yaray
AYArzu Yay
Arzu Yay
Radiation induces pronounced and widespread histopathological damage in the testes, which exhibit a high degree of radiosensitivity; consequently, the utilization of effective radioprotective agents has become increasingly crucial for mitigating radiation-associated toxic outcomes, particularly infertility. The present investigation aimed to comprehensively evaluate the capacity of selenium-L-methionine to mitigate radiation-induced histopathological and molecular alterations within testicular tissue, thereby assessing its potential as a radioprotective agent. Rats were randomized into four groups: Group 1 (control), Group 2 (rad group), which received a single 10 Gy irradiation on day 2; Group 3 (sel group), which received intraperitoneal selenium-L-methionine (4 mg/kg) for six consecutive days; and Group 4 (rad+sel group), which received the same selenium-L-methionine regimen followed by 10 Gy irradiation 30 minutes after the second day's administration. On the seventh day, all animals were euthanized, and testicular tissue and blood samples were collected for biochemical and histopathological analyses. In the testicular tissues of the radiation-exposed groups, deformed and abnormal seminiferous tubule structures, a reduction in germ cell numbers, and sloughing of tubular epithelial cells were observed. Seminiferous tubule diameters, Johnsen's testicular biopsy scores, epididymal sperm motility, and the expression levels of Connexin 43, HSP70, PCNA, StAR, CAT, and SOD were decreased in the irradiated group, whereas TGFB1, IL-6, and MMP9 levels were increased. Selenium-L-methionine treatment largely reversed these radiation-induced changes. The addition of selenium-L-methionine to radiotherapy yielded promising radioprotective outcomes, and this therapeutic effect positions selenium-L-methionine as a potential novel radioprotective agent. Furthermore, the immunohistochemical markers used in the study-including MMP9, Connexin 43, HSP70, PCNA, and StAR served as sensitive indicators for detecting radiation-induced damage in testicular tissue. Nevertheless, larger-scale and long-term studies are required to validate these findings and to further substantiate the potential use of selenium-L-methionine as a radioprotective agent in clinical practice.